This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, K. Articles by Kudo, T. Search for Related Content PubMed PubMed Citation Articles by Nakamura, K. Articles by Kudo, T.

Down-Regulation of the Insulin-like Growth Factor I Receptor by Antisense RNA Can Reverse the Transformed Phenotype of Human Cervical Cancer Cell Lines¹

Department of Obstetrics and Gynecology, Okayama University Medical School, Okayama 700-8558, Japan

The insulin-like growth factor I receptor (IGF-IR) plays an essential role in the establishment and maintenance of transformed phenotype, and interference with the IGF-IR pathway by antisense or dominant-negative mutants causes reversal of the transformed phenotype in many rodent and human tumor cell lines. We stably transfected an IGF-IR antisense mRNA expression plasmid into human papillomavirus (HPV)-negative C33a cell line, HPV-16-positive SiHa cell line, and HPV-18-positive HeLa S3 cell line to determine whether the IGF-IR could be a target for cervical cancer cells, especially in the presence of HPV. Approximately 30–80% down-regulation of IGF-IR expression was observed by Western blot in antisense transfected clones. There was a little inhibition in monolayer growth in all cell lines. In C33a cells, wild-type and sense clones formed 92–146 colonies in soft agar after 3 weeks; antisense clones formed <12 colonies. In SiHa cells, wild-type and sense clones formed 60 colonies after 5 weeks; antisense clones formed 0–3 colonies. In HeLa S3 cells, wild-type and sense clones formed 218–291 colonies in soft agar after 2 weeks; antisense clones formed 14–160 colonies. There was a good correlation between IGF-IR down-regulation level and inhibition of transformation in soft agar. Tumorigenesis in nude mice was strongly inhibited in HeLa S3 and SiHa clones transfected with the antisense. These results indicate that down-regulation of IGF-IR by antisense RNA can reverse the transformed phenotype of human cervical cancer cells, even when harboring malignant type HPVs.

This article has been cited by other articles:

				T. G. Harris, R. D. Burk, H. Yu, H. Minkoff, L. S. Massad, D. H. Watts, Y. Zhong, S. Gange, R. C. Kaplan, K. Anastos, et al. Insulin-Like Growth Factor Axis and Oncogenic Human Papillomavirus Natural History Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 245 - 248. [Abstract] [Full Text] [PDF]

				M. Li, Z. He, S. Ermakova, D. Zheng, F. Tang, Y.-Y. Cho, F. Zhu, W.-Y. Ma, Y. Sham, E. A. Rogozin, et al. Direct Inhibition of Insulin-Like Growth Factor-I Receptor Kinase Activity by (-)-Epigallocatechin-3-Gallate Regulates Cell Transformation Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 598 - 605. [Abstract] [Full Text] [PDF]

				A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF]

				M.-R. Shen, Y.-M. Hsu, K.-F. Hsu, Y.-F. Chen, M.-J. Tang, and C.-Y. Chou Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by {alpha}v{beta}3 integrin signaling Carcinogenesis, May 1, 2006; 27(5): 962 - 971. [Abstract] [Full Text] [PDF]

				K. L. Gable, B. A. Maddux, C. Penaranda, M. Zavodovskaya, M. J. Campbell, M. Lobo, L. Robinson, S. Schow, J. A. Kerner, I. D. Goldfine, et al. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol. Cancer Ther., April 1, 2006; 5(4): 1079 - 1086. [Abstract] [Full Text] [PDF]

				A. Yamamoto, M. L. Cremona, and J. E. Rothman Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway J. Cell Biol., February 27, 2006; 172(5): 719 - 731. [Abstract] [Full Text] [PDF]

				A. Kaneda and A. P. Feinberg Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk Cancer Res., December 15, 2005; 65(24): 11236 - 11240. [Abstract] [Full Text] [PDF]

				A. Hongo, H. Kuramoto, Y. Nakamura, K. Hasegawa, K. Nakamura, J. Kodama, and Y. Hiramatsu Antitumor Effects of a Soluble Insulin-Like Growth Factor I Receptor in Human Ovarian Cancer Cells: Advantage of Recombinant Protein Administration in Vivo Cancer Res., November 15, 2003; 63(22): 7834 - 7839. [Abstract] [Full Text] [PDF]

				G. Blum, A. Gazit, and A. Levitzki Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics J. Biol. Chem., October 17, 2003; 278(42): 40442 - 40454. [Abstract] [Full Text] [PDF]

				S. Baars, A. Bachmann, A. Levitzki, and F. Rosl Tyrphostin AG 555 Inhibits Bovine Papillomavirus Transcription by Changing the Ratio between E2 Transactivator/Repressor Function J. Biol. Chem., September 26, 2003; 278(39): 37306 - 37313. [Abstract] [Full Text] [PDF]

				X. Wu, G. Tortolero-Luna, H. Zhao, D. Phatak, M. R. Spitz, and M. Follen Serum Levels of Insulin-like Growth Factor I and Risk of Squamous Intraepithelial Lesions of the Cervix Clin. Cancer Res., August 1, 2003; 9(9): 3356 - 3361. [Abstract] [Full Text] [PDF]

				D. E. Hansel, A. Rahman, M. Hidalgo, P. J. Thuluvath, K. D. Lillemoe, R. Shulick, J.-L. Ku, J.-G. Park, K. Miyazaki, R. Ashfaq, et al. Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology Am. J. Pathol., July 1, 2003; 163(1): 217 - 229. [Abstract] [Full Text] [PDF]

				J. I. Leu, M. A. S. Crissey, L. E. Craig, and R. Taub Impaired Hepatocyte DNA Synthetic Response Posthepatectomy in Insulin-Like Growth Factor Binding Protein 1-Deficient Mice with Defects in C/EBP{beta} and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Regulation Mol. Cell. Biol., February 15, 2003; 23(4): 1251 - 1259. [Abstract] [Full Text] [PDF]

				N. Reinmuth, W. Liu, F. Fan, Y. D. Jung, S. A. Ahmad, O. Stoeltzing, C. D. Bucana, R. Radinsky, and L. M. Ellis Blockade of Insulin-like Growth Factor I Receptor Function Inhibits Growth and Angiogenesis of Colon Cancer Clin. Cancer Res., October 1, 2002; 8(10): 3259 - 3269. [Abstract] [Full Text] [PDF]

				M. Tezuka, H. Watanabe, S. Nakamura, D. Yu, W. Aung, T. Sasaki, H. Shibuya, and M. Miura Antiapoptotic Activity Is Dispensable for Insulin-like Growth Factor I Receptor-mediated Clonogenic Radioresistance after {gamma}-Irradiation Clin. Cancer Res., October 1, 2001; 7(10): 3206 - 3214. [Abstract] [Full Text] [PDF]

				K. Reiss, X. Tu, G. Romano, F. Peruzzi, J. Y. Wang, and R. Baserga Intracellular Association of a Mutant Insulin-like Growth Factor Receptor with Endogenous Receptors Clin. Cancer Res., July 1, 2001; 7(7): 2134 - 2144. [Abstract] [Full Text] [PDF]

				A. Muratovska, R. N. Lightowlers, R. W. Taylor, D. M. Turnbull, R. A. J. Smith, J. A. Wilce, S. W. Martin, and M. P. Murphy Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease Nucleic Acids Res., May 1, 2001; 29(9): 1852 - 1863. [Abstract] [Full Text] [PDF]